Tirzepatide

Tirzepatide is a synthetic, once-weekly injectable peptide, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Unlike semaglutide, it activates two hormone receptors (GIP and GLP-1) instead of one. In the only trial that directly compared it against semaglutide, tirzepatide produced roughly 48 percent more weight loss when both drugs were dosed to each person’s maximum tolerated amount. Its own cardiovascular outcomes trial, however, narrowly missed statistically proving it was better than an existing active drug, a materially different and less definitive result than semaglutide’s placebo-controlled cardiovascular trial.

Ask about Tirzepatide

Research snapshot

CategoryCurrent information
Peptide categoryDual GIP/GLP-1 receptor agonist, synthetic peptide
Primary research interestType 2 diabetes, chronic weight management, obstructive sleep apnea
Highest available evidenceTier 1: multiple published human clinical trials, including a head-to-head trial against semaglutide (SURMOUNT-5) and a cardiovascular outcomes trial (SURPASS-CVOT)
Human research availableYes: extensive; FDA-approved with a large published trial record
Development statusFully developed, approved pharmaceutical (Mounjaro, Zepbound)
Regulatory statusFDA approved for multiple indications; carries a boxed warning for thyroid C-cell tumors seen in rodent studies

Technical identity

Technical propertyInformation
Primary nameTirzepatide
Alternative namesMounjaro, Zepbound (brand names)
Peptide sequence39 amino acid dual GIP/GLP-1 receptor agonist, Aib at positions 2 and 13, C20 fatty diacid attached to the Lys20 side chain, C-terminal amide
Amino-acid length39
Molecular formulaC225H348N48O68
Molecular weight4813.53 g/mol
CAS Registry Number2023788-19-2
Chemical modificationsAcylated (C20 fatty diacid) dual GIP/GLP-1 analogue for albumin binding, half-life about 5 days
Peptide classDual incretin receptor agonist (twincretin)
Primary biological targetGIP receptor and GLP-1 receptor
Developer / originatorEli Lilly and Company
Development statusApproved prescription drug, multiple formulations and indications

What it is

Tirzepatide is a synthetic 39 amino acid dual GIP and GLP-1 receptor agonist, acylated for albumin binding. Molecular weight 4813.53 Da. The half-life is about five days, longer than semaglutide’s one week measured in absolute terms but shorter in half-lives per dosing interval, which is part of why its label allows a 4-week titration step rather than semaglutide’s minimum-4-week convention with more common 4-week steps in practice.

Figures in this table summarize dosing described in FDA-approved prescribing information. Their inclusion documents the approved regimen and does not establish what any individual reader should take, that is a decision for a prescriber. This site does not reproduce dosing information for compounded or grey-market tirzepatide; the FDA has logged hundreds of adverse event reports tied to compounded versions, including products containing salt forms not present in the approved drug.

ProductIndicationStarting doseEscalationMaximum approved doseEvidence category
MounjaroType 2 diabetes2.5 mg weekly for 4 weeks (not intended to be therapeutic)5 mg, then 2.5 mg increments after at least 4 weeks per step15 mg weeklyFDA-approved prescribing information
ZepboundChronic weight management2.5 mg weekly for 4 weeks5 mg, then 2.5 mg increments every 4 weeks as tolerated10 or 15 mg weekly (maintenance)FDA-approved prescribing information
ZepboundObstructive sleep apnea (since Dec 2024)2.5 mg weekly for 4 weeksSame escalation; no 5 mg maintenance option for this indication10 or 15 mg weekly (maintenance only)FDA-approved prescribing information

What is approved, and at what dose

A record of what the FDA had approved as of 17 September 2026, not an instruction.

Mounjaro, for type 2 diabetes: 2.5 mg weekly for 4 weeks as a starting dose that is not intended to be therapeutic, then 5 mg. If needed, escalate by 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly.

Zepbound, for chronic weight management and, since 20 December 2024, moderate-to-severe obstructive sleep apnoea in adults with obesity: the same 2.5 mg for 4 weeks starting dose, then 5 mg, escalating by 2.5 mg every 4 weeks as tolerated to a maintenance dose of 10 or 15 mg. For OSA specifically the label does not carry a lower 5 mg maintenance option; only 10 and 15 mg are indicated maintenance doses.

Both products share one escalation schedule and one titration logic; they differ in indication and in which maintenance doses the label emphasizes. There is no 5 mg per week ceiling and no plateau below 10 mg described anywhere in either label as a stopping point, though a person and their prescriber can choose to stay on a lower dose if it is effective and tolerated.

Every tirzepatide product carries the same boxed warning for thyroid C-cell tumours seen in rodents, with human relevance undetermined. Contraindications are limited to hypersensitivity to tirzepatide or any component, and personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Prior pancreatitis is not a contraindication, a common misstatement worth correcting directly.

Potential benefits and research applications

Weight loss, more than single-target incretins in head-to-head testing

What is being investigated: whether activating both GIP and GLP-1 receptors together produces greater weight loss than a GLP-1-only drug. How the effect might occur: dual receptor activation may act on complementary appetite and metabolic pathways. Evidence: SURMOUNT-1 showed up to 20.9 percent weight loss at 72 weeks, and SURMOUNT-5, the only trial comparing it directly to semaglutide, found roughly 48 percent more weight loss with tirzepatide when both drugs were titrated to each person’s maximum tolerated dose. Strength: has been shown in large, FDA-approved-indication trials, including a genuine head-to-head comparison. Limitation: that head-to-head used flexible, individualized dosing rather than fixed doses, so the comparison describes two real-world titration strategies rather than a strict dose-for-dose test.

Type 2 diabetes management

What is being investigated: blood sugar control and weight loss together in people with type 2 diabetes. How the effect might occur: the same dual receptor mechanism, applied to a population with underlying insulin resistance. Evidence: SURMOUNT-2 showed real weight loss and glycemic improvement, though at a smaller magnitude than in people without diabetes. Strength: has been shown in a large randomised trial and is FDA approved specifically for this use. Limitation: the attenuated response in diabetes is a known class-wide pattern across all incretin therapies, not unique to tirzepatide, and should not be read as the drug performing worse in some abnormal way.

Obstructive sleep apnea

What is being investigated: reducing sleep apnea severity in people with obesity, largely as a downstream effect of weight loss. How the effect might occur: reduced upper-airway fat and improved respiratory mechanics following substantial weight reduction. Evidence: two trials supported an FDA approval for this specific indication in December 2024. Strength: has been shown well enough to earn a distinct FDA-approved indication, the only GLP-1/GIP drug with this specific approval as of this review. Limitation: the approved maintenance doses for this indication are limited to 10 and 15 mg, with no lower-dose option on the label.

SURMOUNT-1: the foundational obesity trial

SURMOUNT-1 randomised 2,539 adults with obesity or overweight plus a weight-related comorbidity, without diabetes, to tirzepatide 5, 10 or 15 mg or placebo, weekly, for 72 weeks. On the treatment-regimen estimand, mean weight change was minus 15.0 percent at 5 mg, minus 19.5 at 10 mg, minus 20.9 at 15 mg and minus 3.1 percent on placebo. Discontinuation for adverse events ran 4.3, 7.1 and 6.2 percent across the three tirzepatide doses against 2.6 percent on placebo.

SURMOUNT-2: the diabetes population, and why the number looks smaller

SURMOUNT-2 enrolled 938 adults with type 2 diabetes and obesity or overweight. Weight loss came in lower, minus 14.7 percent at the top dose, against minus 20.9 in SURMOUNT-1. This is not a weaker drug in diabetes; it is the same well-documented attenuation of weight-loss response seen with every incretin therapy in a diabetic population, driven by differences in insulin physiology and disease duration, not a property specific to tirzepatide.

SURMOUNT-5: the only head-to-head, and what it actually compared

SURMOUNT-5 randomised 751 adults with obesity or overweight, without diabetes, to tirzepatide, maximum tolerated dose up to 15 mg, or semaglutide, maximum tolerated dose up to 2.4 mg, open-label, for 72 weeks. This is the only trial anywhere comparing tirzepatide against another approved incretin therapy rather than against placebo.

On the modified treatment-regimen estimand, tirzepatide produced minus 20.2 percent weight loss against minus 13.7 percent for semaglutide, meaning roughly 48 percent more weight loss with tirzepatide in this trial. Gastrointestinal-related discontinuation ran lower with tirzepatide, 2.7 percent against 5.6 percent for semaglutide, and vomiting was less frequent, 15.0 against 21.3 percent. Both drugs were dosed to each participant’s maximum tolerated dose rather than a fixed dose, which is the correct way to read “48 percent more”: it compares two real-world titration strategies, not 15 mg against 2.4 mg as fixed doses.

The cardiovascular trial that surprised people

SURPASS-CVOT randomised 13,299 adults with type 2 diabetes and established cardiovascular disease to tirzepatide or dulaglutide 1.5 mg, median follow-up 210 weeks. The primary MACE endpoint gave a hazard ratio of 0.92, 95 percent CI 0.83 to 1.01, meeting the prespecified non-inferiority margin but narrowly missing statistical superiority: the confidence interval’s upper bound sits at 1.01, just above the 1.00 threshold superiority requires.

This is a genuinely different result from semaglutide’s SELECT trial, which showed clear MACE superiority against placebo. SURPASS-CVOT compared tirzepatide against another active glucose-lowering therapy known to have cardiovascular benefit, not against placebo, which is a much harder bar to clear. A post hoc composite cardiorenal endpoint reported in June 2026 showed a hazard ratio of 0.84, but this was not a primary or confirmatory analysis and should not be read as an established cardiovascular protection claim the way SELECT’s MACE reduction can be.

SURMOUNT-4: what happens on withdrawal

In SURMOUNT-4, 670 participants who had completed a 36-week open-label lead-in on tirzepatide, during which the group had lost a mean 20.9 percent of body weight, were then randomised to continue tirzepatide or switch to placebo for a further 52 weeks. Those continuing lost an additional 5.5 percent; those switched to placebo regained, ending 14.0 percent above their week-36 weight. This is a randomised withdrawal design, the cleanest way to isolate what continued treatment versus stopping actually does, free of the confounding that comes from people switching therapies or restarting on their own in open-label follow-up.

A separate open-label extension, SURMOUNT-MAINTAIN, followed 378 people after treatment discontinuation without randomisation to a control arm, and found regain at 8 percent by some point, 25 percent by a later point and 67 percent by the final assessment, of the weight originally lost. These are different designs measuring different things: SURMOUNT-4 isolates the drug effect under controlled conditions; SURMOUNT-MAINTAIN describes what happens in a less controlled real-world-adjacent setting where people are not held to a fixed alternative.

Tirzepatide was not part of the Italian cohort that reported a death hazard ratio of 4.81 after GLP-1 discontinuation, because it reached the market after the data ended. The analysis of that study explains what the number does and does not show.

Body composition: the DXA substudy

A dedicated dual-energy X-ray absorptiometry substudy of SURMOUNT-1, in a subset of 160 participants, found that at the top dose, total weight fell 21.3 percent, fat mass fell 33.9 percent and lean mass fell 10.9 percent. Reporting only the lean mass percentage without the accompanying fat mass percentage, as some secondary sources do, obscures that fat loss substantially outpaced lean loss. A broader 2026 review found a class-wide median of 28.3 percent of total weight lost coming from lean-mass-associated measures, tirzepatide included, which is consistent with, not contradictory to, the DXA substudy’s dose-specific figures. Bimagrumab has also been paired with tirzepatide in a separate phase 2 study; our BELIEVE trial analysis covers the earlier semaglutide-based trial and what it did and did not show about muscle.

What tirzepatide has not been shown to do

A phase 2 trial, SUMMIT, tested tirzepatide in heart failure with preserved ejection fraction and reported a positive result on its combined endpoint, but Lilly voluntarily withdrew the associated supplemental indication filing in May 2025, stating that a second, larger confirmatory trial would be required before an indication could be supported. As of 17 September 2026 there is no approved indication for heart failure, HFpEF specifically, and the SUMMIT result should be described as promising phase 2 data awaiting confirmation, not as an established benefit.

Eye safety (NAION). On 9 November 2026 Reuters reported that the FDA is requiring GLP-1 drug labels, with Mounjaro, Zepbound, Ozempic and Wegovy named as examples, to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of sudden painless vision loss, to Warnings and Precautions (Reuters report via Yahoo News). The exact label wording had not been confirmed from an FDA document when this page was updated. Earlier reporting-database work found a much weaker signal for tirzepatide than for semaglutide, with reporting odds ratios of 2.94 and 94.45 (Kakkar et al., Diabetes, Obesity and Metabolism 2026, PMID 42259643), but reports of that kind cannot show that a drug causes an event.

Regulatory and manufacturing history

Mounjaro was approved 13 May 2022; Zepbound followed 8 November 2023. The FDA declared the tirzepatide shortage resolved on 2 October 2024. Lilly petitioned to keep compounding restricted regardless via a citizen petition and the FDA issued a declaratory order narrowing the essentially-a-copy exemption on 19 December 2024; enforcement discretion for 503A compounders ended 18 February 2025 and for 503B outsourcing facilities 19 March 2025. A district court challenge to the shortage-resolved determination was rejected and the FDA’s position was upheld on 7 May 2025. By 31 May 2026 the FDA held more than 730 adverse event reports associated with compounded tirzepatide products, including reports naming salt forms not present in the approved drug.

The OSA indication for Zepbound was approved 20 December 2024, on the strength of two trials, and the label for that indication specifically excludes a 5 mg maintenance dose, using only 10 and 15 mg.

What circulates, and why no numbers appear here

This site does not reproduce dosing regimens for tirzepatide beyond the approved label. Every figure here is the modified treatment-regimen estimand, unless stated otherwise, and it describes what a specific trial did, not a protocol to follow. The approved titration exists because tolerability failures compound: skipping steps or inventing intermediate doses not on the label is one of the dosing-error patterns the FDA has linked to adverse events in the compounded tirzepatide market described above.

Frequently asked questions

What is tirzepatide?

A dual GIP and GLP-1 receptor agonist, FDA approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. It activates two hormone receptors, where semaglutide activates one.

How does it work?

It activates both the GIP and GLP-1 receptors together, suppressing appetite and slowing gastric emptying, similar in overall effect to semaglutide but through an additional pathway.

What dosage has been approved?

Both Mounjaro and Zepbound escalate from a non-therapeutic 2.5 mg weekly starting dose to 5 mg, then in 2.5 mg increments at least four weeks apart, up to a maximum of 15 mg weekly. The obstructive sleep apnea indication only recognizes 10 and 15 mg as maintenance doses.

Is tirzepatide better than semaglutide?

In the one trial that compared them directly, both dosed to each person’s maximum tolerated amount, tirzepatide produced about 48 percent more weight loss and slightly fewer gastrointestinal side effects. That is a real, trial-confirmed difference, though it compares two flexible dosing strategies rather than fixed milligram-for-milligram doses.

Does it protect the heart the way semaglutide does?

Not to the same degree of proof. Tirzepatide’s cardiovascular trial compared it against another active diabetes drug, not placebo, and narrowly missed showing statistical superiority. Semaglutide’s trial compared it against placebo and showed a clear, confirmed reduction in cardiac events. This does not mean tirzepatide is unsafe for the heart, but the two drugs do not have equivalent cardiovascular evidence.

What dosage commonly circulates from unregulated sources?

This site does not reproduce dosing information for compounded or grey-market tirzepatide. The FDA has logged hundreds of adverse event reports tied to compounded versions, including products containing salt forms not present in the approved drug.

What happens if you stop taking it?

A randomised trial found people who switched to placebo after losing weight on tirzepatide regained substantially, ending up well above their weight at the point they stopped. A separate, less controlled follow-up found regain climbing over time, reaching a majority of the lost weight by the final assessment for many participants.

What side effects have been reported?

Mostly gastrointestinal (nausea, vomiting, diarrhea), similar to semaglutide but with somewhat lower discontinuation rates in the head-to-head comparison. It carries the same boxed warning for thyroid C-cell tumors seen in rodent studies. Prior pancreatitis is not a contraindication, contrary to a common misconception.

What remains unknown?

Whether it provides a confirmed cardiovascular mortality benefit, whether a positive early heart-failure signal will hold up in a larger confirmatory trial (the initial filing for that indication was withdrawn), and whether lean-tissue loss affects physical function or strength.

Bottom line

Tirzepatide is a well-evidenced, FDA-approved drug that outperformed semaglutide on weight loss in the one trial that compared them head-to-head, with a modestly better tolerability profile. Its cardiovascular evidence, though, is less definitive than semaglutide’s: it was tested against an active comparator rather than placebo and narrowly missed statistical superiority. A promising heart-failure signal has not yet been confirmed and the associated approval filing was withdrawn pending further study. Weight regain after stopping is substantial and well documented, and compounded, unregulated versions carry real safety concerns the FDA has flagged directly.

Related entries: retatrutide, the GIP, GLP-1 and glucagon triple agonist; mazdutide, a GLP-1 and glucagon dual agonist; orforglipron, an oral non-peptide GLP-1 agonist.

Label doses, every trial dose and the amounts that circulate online are laid out in the tirzepatide dosage guide.

Trial analysis: the TOGETHER-PsA 52-week analysis reviews the open-label trial of tirzepatide added to ixekizumab in psoriatic arthritis with obesity.

Sources

  1. MOUNJARO (tirzepatide) injection prescribing information, Eli Lilly and Company, revised 08/2026. Source for the type 2 diabetes indication, the 2.5 to 15 mg titration schedule, the boxed warning and the contraindications. Human, regulatory. pi.lilly.com/us/mounjaro-uspi.pdf
  2. ZEPBOUND (tirzepatide) injection prescribing information, US Food and Drug Administration, revised 01/2026. Source for the chronic weight management and obstructive sleep apnoea indications, the 10 and 15 mg OSA maintenance doses, and the December 2024 OSA approval. Human, regulatory. NDA 217806
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. Human randomised trial, n=2,539. Weight change minus 15.0, 19.5 and 20.9 percent at 5, 10 and 15 mg versus minus 3.1 percent placebo; discontinuation for adverse events 4.3, 7.1 and 6.2 versus 2.6 percent. PMID 35658024
  4. Look M, et al. Body composition changes with tirzepatide in the SURMOUNT-1 dual-energy X-ray absorptiometry substudy. Diabetes Obes Metab. 2025. Human, n=160 substudy. Source for the -21.3% total weight, -33.9% fat mass and -10.9% lean mass figures at the top dose. PMID 39996356
  5. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626. Human randomised trial, n=938. Weight change up to minus 14.7 percent at the top dose, the diabetes-population attenuation this entry describes. PMID 37385280
  6. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024;331:38-48. Human randomised withdrawal trial, n=670 randomised after a 36-week lead-in. Continued tirzepatide minus 5.5 percent further; placebo switch plus 14.0 percent regain from week 36. PMID 38151585
  7. Aronne LJ, et al. Tirzepatide vs Semaglutide for Treatment of Adults With Obesity. JAMA. 2025. Human randomised open-label trial, n=751. Modified treatment-regimen estimand: minus 20.2 versus minus 13.7 percent; GI discontinuation 2.7 versus 5.6 percent; vomiting 15.0 versus 21.3 percent. The only head-to-head trial against another approved incretin therapy. PMID 40163401
  8. Open-label extension following tirzepatide discontinuation, n=378. Regain of 8, 25 and 67 percent of lost weight at successive assessment points, without randomisation to a placebo control, distinct in design from the randomised withdrawal in SURMOUNT-4. NCT06047548
  9. Nicholls SJ, et al. Tirzepatide versus Dulaglutide in Type 2 Diabetes and Cardiovascular Disease. N Engl J Med. 2025. Human randomised trial, n=13,299, median follow-up 210 weeks. MACE hazard ratio 0.92, 95% CI 0.83 to 1.01, non-inferior but not statistically superior against an active comparator. PMID 40636479
  10. Post hoc composite cardiorenal endpoint analysis of SURPASS-CVOT, reported June 2026, hazard ratio 0.84. Not a primary or confirmatory endpoint. Packer 2026, June
  11. Phase 2 SUMMIT trial of tirzepatide in HFpEF, positive combined endpoint reported, but the associated supplemental indication filing was voluntarily withdrawn by Eli Lilly in May 2025 pending a larger confirmatory trial. No approved indication as of 17 September 2026. Rosenkilde 2026
  12. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026;179:996-1013. Human systematic review of 35 randomised trials, tirzepatide included. Median 28.3 percent of weight loss from muscle-based indices, no study reporting objective physical function. PMID 41996180
  13. Review of dual GIP/GLP-1 receptor agonism mechanism, supporting the pharmacological rationale for tirzepatide's dual-agonist effect relative to single-agonist incretins. Gao 2026
  14. US Food and Drug Administration declaratory order, 19 December 2024, narrowing the essentially-a-copy exemption relied on by tirzepatide compounders. Regulatory. FDA media 184606
  15. US Food and Drug Administration. Tirzepatide shortage determined resolved 2 October 2024; 503A enforcement discretion ended 18 February 2025 and 503B 19 March 2025; district court challenge to the shortage-resolved determination rejected, FDA position upheld 7 May 2025. Regulatory. FDA compounding policy statement, 2024-2025
  16. US Food and Drug Administration. More than 730 adverse event reports for compounded tirzepatide products as of 31 May 2026, including reports naming salt forms not present in the approved drug. Regulatory. FDA safety communication, data as of 31 May 2026

Research area: Metabolic and incretin.

Share thisFacebookXEmail